期刊
EUROPEAN RESPIRATORY REVIEW
卷 31, 期 163, 页码 -出版社
EUROPEAN RESPIRATORY SOC JOURNALS LTD
DOI: 10.1183/16000617.0176-2021
关键词
-
资金
- Novartis Pharma, Basel, Switzerland
- Novartis
Asthma patients often have poor asthma control, which not only affects the patients themselves but also burdens society. Solutions such as shared decision-making, good patient-clinician communication, self-management, multidisciplinary education, and new technology may help improve asthma control.
Despite the availability of effective inhaled therapies, many patients with asthma have poor asthma control. Uncontrolled asthma presents a significant burden on the patient and society, and, for many, remains largely preventable. There are numerous reasons why a patient may remain uncontrolled despite access to therapies, including incorrect inhaler technique, poor adherence to treatment, oversight of triggers and suboptimal medical care. Shared decision-making, good patient-clinician communication, supported self-management, multidisciplinary patient education, new technology and risk stratification may all provide solutions to this major unmet need in asthma. Novel treatments such as biologics could benefit patients' lives, while the investigations into biomarkers, non-Type 2 asthma, treatable traits and disease modification give an exciting glimpse into the future of asthma care.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据